四组分B群脑膜炎球菌疫苗在婴儿中诱导针对C、W、Y群侵袭性菌株的交叉反应性免疫
该研究评估4CMenB疫苗接种婴儿后血清抗体对非B群脑膜炎球菌的杀菌能力。共收集227株非B群侵袭性分离株,选取147株代表遗传多样性进行hSBA检测,结果显示109株被杀死,总体覆盖率为74%。结论支持4CMenB在婴儿中可提供针对非B群菌株的交叉保护。
要点
- 4CMenB免疫婴儿血清对147株非B群菌株中109株具杀菌活性,覆盖率74%。
- 非B群菌株的血清群和克隆复合体分布因国家而异。
- 数据支持4CMenB接种对非B群菌株的交叉保护作为附加获益。
核心结论
- 4CMenB免疫婴儿诱导的抗体可杀死109株非B群脑膜炎球菌,总体覆盖率74%,支持交叉保护。
研究设计与样本
- 研究收集2007年7月至2008年6月来自英格兰、威尔士、法国和德国的227株非B群侵袭性分离株,以及2012年巴西的41株分离株,进行基因型分析。
- 选取147株代表总样本遗传多样性的MenC、MenW和MenY分离株,使用4CMenB免疫婴儿血清进行人补体血清杀菌抗体试验(hSBA)。
主要发现
- 非B群分离株的血清群和克隆复合体组成各国不同;欧洲面板中MenC、MenW和MenY主要分别属于ST-11、ST-22和ST-23复合体。
- 巴西面板中大多数MenC和MenW分别属于ST-103和ST-11复合体,大多数MenY未归入克隆复合体。
- 147株非B群分离株中109株在hSBA中被杀死,总体覆盖率为74%。
临床怎么用
- 4CMenB接种除预防B群侵袭性 meningococcal 病外,可能对C、W、Y群菌株提供交叉保护,支持其附加获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The multicomponent meningococcal serogroup B vaccine (4CMenB) is currently indicated for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB). However, genes encoding the 4CMenB antigens are also variably present and expressed in strains belonging to other meningococcal serogroups. In this study, we evaluated the ability of antibodies raised by 4CMenB immunisation to induce complement-mediated bactericidal killing of non-MenB strains. METHODS: A total of 227 invasive non-MenB disease isolates were collected between 1 July 2007 and 30 June 2008 from England and Wales, France, and Germany; 41 isolates were collected during 2012 from Brazil. The isolates were subjected to genotypic analyses. A subset of 147 isolates (MenC, MenW and MenY) representative of the meningococcal genetic diversity of the total sample were tested in the human complement serum bactericidal antibody assay (hSBA) using sera from infants immunised with 4CMenB. RESULTS: Serogroup and clonal complex repertoires of non-MenB isolates were different for each country. For the European panel, MenC, MenW and MenY isolates belonged mainly to ST-11, ST-22 and ST-23 complexes, respectively. For the Brazilian panel, most MenC and MenW isolates belonged to the ST-103 and ST-11 complexes, respectively, and most MenY isolates were not assigned to clonal complexes. Of the 147 non-MenB isolates, 109 were killed in hSBA, resulting in an overall coverage of 74%. CONCLUSION: This is the first study in which 147 non-MenB serogroup isolates have been analysed in hSBA to evaluate the potential of a MenB vaccine to cover strains belonging to other serogroups. These data demonstrate that antibodies raised by 4CMenB are able to induce bactericidal killing of 109 non-MenB isolates, representative of non-MenB genetic and geographic diversity. These findings support previous evidence that 4CMenB immunisation can provide cross-protection against non-MenB strains in infants, which represents an added benefit of 4CMenB vaccination.
引用
- Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020. PMID: 33036804. doi:10.1016/j.vaccine.2020.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。